This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodeheffer, R. J. Search for Related Content PubMed PubMed Citation Articles by Rodeheffer, R. J.

Measuring plasma B-type natriuretic peptide in heart failure

Good to go in 2004?

Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MinnesotaUSA

View larger version (40K): [in a new window]   Figure 1 Schematic diagram depicting the mechanism by which cardiac secretion of natriuretic peptides serves to maintain intravascular volume homeostasis. ANP = atrial natriuretic peptide; BNP = B-type natriuretic peptide; LA = left atrium; RA = right atrium; LVEDP = left ventricular end-diastolic pressure; RAAS = renin-angiotensin-aldosterone system; RVEDP = right ventricular end-diastolic pressure.

View larger version (21K): [in a new window]   Figure 2 Plasma atrial natriuretic peptide (ANP) concentrations in normal subjects, asymptomatic cardiovascular (CV) disease subjects with normal or elevated pulmonary capillary wedge pressures (PCW), and symptomatic heart failure patients (CHF) with elevated PCW pressure. (Adapted, with permission, from Burnett JC Jr., Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986;231:1145–7.)

View larger version (20K): [in a new window]   Figure 3 Cumulative incidence of heart failure according to plasma B-type natriuretic peptide level at baseline in Framingham participants. (Adapted, with permission from Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655–63.)